磷酸甘油酸脱氢酶通过增加还原型谷胱甘肽合成促进多发性骨髓瘤增殖和硼替佐米耐药
本研究探讨丝氨酸合成途径限速酶PHGDH在多发性骨髓瘤硼替佐米耐药中的作用。发现复发患者CD138+细胞中PHGDH显著升高且高表达与生存不良相关;PHGDH过表达促进细胞生长、成瘤和硼替佐米耐药,而抑制PHGDH可逆转耐药;机制上PHGDH通过增加GSH合成降低ROS。
要点
- 复发MM患者CD138+细胞中PHGDH显著升高,高PHGDH与生存不良相关
- PHGDH过表达促进MM细胞生长、成瘤和硼替佐米耐药
- 抑制PHGDH可抑制细胞生长和硼替佐米耐药
核心结论
- PHGDH通过增加GSH合成降低ROS,促进MM细胞增殖和硼替佐米耐药。
- 靶向PHGDH是MM治疗的有前景策略。
研究设计与样本
- 研究检测了复发MM患者CD138+细胞中PHGDH表达,并在体外和体内进行PHGDH过表达和抑制实验。
主要发现
- 复发MM患者CD138+细胞中PHGDH显著升高,高PHGDH与生存不良相关。
- PHGDH过表达增加MM细胞生长、成瘤和硼替佐米耐药。
- shRNA或NCT-503抑制PHGDH可抑制MM细胞生长和硼替佐米耐药。
- PHGDH通过增加GSH合成降低ROS。
- 添加GSH可逆转PHGDH沉默MM细胞的S期阻滞和硼替佐米诱导的细胞死亡。
临床怎么用
- PHGDH表达水平可能作为MM预后和硼替佐米耐药参考指标。
- 靶向PHGDH(如NCT-503)可能成为克服硼替佐米耐药的策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The serine synthesis pathway (SSP) is active in multiple cancers. Previous study has shown that bortezomib (BTZ) resistance is associated with an increase in the SSP in multiple myeloma (MM) cells; however, the underlying mechanisms of SSP-induced BTZ resistance remain unclear. In this study, we found that phosphoglycerate dehydrogenase (PHGDH), the first rate-limiting enzyme in the SSP, was significantly elevated in CD138+ cells derived from patients with relapsed MM. Moreover, high PHGDH conferred inferior survival in MM. We also found that overexpression of PHDGH in MM cells led to increased cell growth, tumour formation, and resistance to BTZ in vitro and in vivo, while inhibition of PHGDH by short hairpin RNA or NCT-503, a specific inhibitor of PHGDH, inhibited cell growth and BTZ resistance in MM cells. Subsequent mechanistic studies demonstrated PHGDH decreased reactive oxygen species (ROS) through increasing reduced glutathione (GSH) synthesis, thereby promoting cell growth and BTZ resistance in MM cells. Furthermore, adding GSH to PHGDH silenced MM cells reversed S phase arrest and BTZ-induced cell death. These findings support a mechanism in which PHGDH promotes proliferation and BTZ resistance through increasing GSH synthesis in MM cells. Therefore, targeting PHGDH is a promising strategy for MM therapy.
引用
- Wu X, Xia J, Zhang J, et al. Phosphoglycerate dehydrogenase promotes proliferation and bortezomib resistance through increasing reduced glutathione synthesis in multiple myeloma. Br J Haematol. 2020. PMID: 32037523. doi:10.1111/bjh.16503
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。